The Association Between Heterosexual anal Intercourse and HIV Acquisition in Three Prospective Cohorts of Women
Year: 2023
Type: article
Abstract: The extent to which receptive anal intercourse (RAI) increases the HIV acquisition risk of women compared to receptive vaginal intercourse (RVI) is poorly understood. We evaluated RAI practice over time and its association with HIV incidence during three prospective HIV cohorts of women: RV217, MTN-003 (VOICE), and HVTN 907. At baseline, 16% (RV 217), 18% (VOICE) of women reported RAI in the past 3 months and 27% (HVTN 907) in the past 6 months, with RAI declining during follow-up by around 3-fold. HIV incidence in the three cohorts was positively associated with reporting RAI at baseline, albeit not always significantly. The adjusted hazard rate ratios for potential confounders (aHR) were 1.1 (95% Confidence interval: 0.8-1.5) for VOICE and 3.3 (1.6-6.8) for RV 217, whereas the ratio of cumulative HIV incidence by RAI practice was 1.9 (0.6-6.0) for HVTN 907. For VOICE, the estimated magnitude of association increased slightly when using a time-varying RAI exposure definition (aHR = 1.2; 0.9-1.6), and for women reporting RAI at every follow-up survey (aHR = 2.0 (1.3-3.1)), though not for women reporting higher RAI frequency (> 30% acts being RAI vs. no RAI in the past 3 months; aHR = 0.7 (0.4-1.1)). Findings indicated precise estimation of the RAI/HIV association, following multiple RVI/RAI exposures, is sensitive to RAI exposure definition, which remain imperfectly measured. Information on RAI practices, RAI/RVI frequency, and condom use should be more systematically and precisely recorded and reported in studies looking at sexual behaviors and HIV seroconversions; standardized measures would aid comparability across geographies and over time.
Source: AIDS and Behavior
Institutions: St Mary's Hospital, Imperial College London, University of Michigan, McGill University, University of California, Davis, University of Pittsburgh, Family Health International 360, University of California, San Francisco, Atmospheric and Space Technology Research Associates (United States), Henry M. Jackson Foundation, Walter Reed Army Institute of Research, University of Alabama at Birmingham, Fred Hutch Cancer Center
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,190
Funders: U.S. Department of Defense, Henry M. Jackson Foundation, University of Washington, European Commission, Foreign, Commonwealth and Development Office, National Institutes of Health, Centers for Disease Control and Prevention, University of California, Los Angeles, Medical Research Council, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, Eunice Kennedy Shriver National Institute of Child Health and Human Development, European and Developing Countries Clinical Trials Partnership
Awards: G1052272520, G127891921, G1311689652, ADDRESSING THE THREATS OF HIV AND EMERGING INFECTIOUS DISEASE TO THE MILITARY AND GLOBAL COMMUNITY THROUGH INNOVATIVE RESEARCH, G1736305949, HVTN Laboratory Program, G2347075150, MRC Centre for Global Infectious Disease Analysis, Statistical and Data Management Center (SDMC): Microbicide Trials Network, Leadership and Operations Center (LOC): Microbicide Trials Network, G3166327464, G347747909, G393184570, G4119534169, G4926557987, GHESKIO HIV Clinical Trial Unit, Development of HIV Vaccine Clinical Trials Phase I-II-III in Dominican Republic, Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials Network, G633733221, HIV-Specific T Cell Responses in Rectal Mucosa, University of Puerto Rico Clinical Trials Unit, G7063735130, Laboratory Center (LC): Microbicide Trials Network, G8093122957, G8166743225, Leadership Group for a Global HIV Vaccine Clinical Trials Network, G9000226676, HIV Vaccine Trials Network Laboratory Center, HIV Prevention Trials Network Leadership and Operations Center, HIV Vaccines Clinical Trials Network Leadership and Operations Center, SDMC: HIV Vaccine Trials Network, Rustbelt Center for AIDS Research (Case/UHC-Pitt CFAR), SDMC: HIV Prevention Trials Network
OpenAlex ID: W4382810716
